The initial hallmark of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pandemic was the virus’ predilection for causing disease, hospitalization, and death among older adults and adults with comorbidities. Yet by September 2021, over six months after 3 highly effective and safe SARS-CoV-2 vaccines were first approved for use in adults, children comprised more than a quarter of all reported cases. In addition, pediatric hospital admissions for coronavirus disease 2019 (COVID-19) were the highest reported since the onset of the pandemic, largely because of the high case load associated with the highly transmissible delta variant of SARS-CoV-2. Although most children continue to fare well after SARS-CoV-2 infection, children with underlying comorbidities carry a greater risk for severe disease. It was unfortunate that children returned to in-person school in summer 2021 with the youngest lacking access to the most powerful tool we have to protect them against SARS-CoV-2: vaccines....

You do not currently have access to this content.